Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Oncogene. 2021 Feb 1;40(11):1927–1941. doi: 10.1038/s41388-020-01577-5

Table 3. Table of all the preclinical studies evidencing the role of MET in chemoresistance and the mechanisms involved.

Cell lines in blue font: paired isogenic chemosensitive and chemoresistant cell lines. (Note - some cell lines placed in the chemosensitive category in this table have been used as a model to study chemoresistance as their chemosensitivity may be reduced). Red box: MET overexpressed in chemoresistant cell line compared to parental cells. Yellow box: constitutive activation of MET. Orange box: MET overexpressed and constitutively active. Green dot: HGF expressed. The darker or lighter green indicate an increase or a decrease of HGF in chemoresistant cells versus chemosensitive cells. NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, PDAC: pancreatic ductal adenocarcinoma, HCC: hepatocellular carcinoma. MET-stimulated cellular functions which promote chemoresistance: A: apoptosis inhibition, R: DNA repair enhancement, CC: cell cycle progression, D: drug efflux, P: increased proliferation, E: increased EMT, S: enhanced cancer stem cells survival and proliferation, AE: altered endothelial cell behaviour, H: increased intra-tumoural hypoxia.

Cancer Chemotherapy Cell model MET/HGF blockade used Functions Refs
Chemosensitive Chemoresistant
Ovarian Paclitaxel SKOV3 and OVCAR-3 n/a Capmatinib (2,4,6,8μM) A, R, CC 55
Cisplatin SKOV3 and 3AO SKOV3DDP, OVCAR3, OV-90 PHA665752 (400nM), KD A 30
Doxorubicin A2780 Inline graphic A2780DR Inline graphic SU11274 (1 or 2μM), KD DE 32
Carboplatin + paclitaxel Multiple n/a MK8033 (8.5-19.2μM) P 54
Paclitaxel SKOV3 and HO-8910 Inline graphic n/a Capmatinib(60nM) A 38
Paclitaxel and cisplatin CaOV-3 and SKOV-3 n/a KD A 49
Cisplatin A2780 and SKOV3 n/a Crizotinib (1 or 3μM) A 56
NSCLC Cisplatin H23, H226, H838, H1437, H2009, H2087, A549 n/a n/a A 46
Cisplatin H1299 H1299/DPP miR-206 mimic, KD E, D 31
Cisplatin A549 A549/DDP SU11274 (0.5μM), KD E, D 31
Cisplatin A549 A549/DPP Salvianolic acid A (10-20μg/ml), KD A, R, D 35
SCLC Etoposide H69 Inline graphic H69M Inline graphic Crizotinib (200nM) E 37
Cisplatin, SN-38, paclitaxel PC-6, NCI-H69 Inline graphic PC-6/SN-28, PC-6/CDDP, PC-6/TXL, H69/TXL Inline graphic SU11274 (0.5 or 2μM), KD A 28
PDAC Gemcitabine Orthotopic. KPC in vivo n/a Capmatinib(1mg/kg), KD A 58
Gemcitabine BxPc-3 BxPc-3-GEM Cabozantinib (10μM) A, S 73
Gemcitabine Capan-1 Capan-1-R Crizotinib (1.5μM) A, S, E, C 36
Gastric SN38 OCUM-2M, OCUM-2D, OCUM-2MD3 OCUM-2M/SP, OCUM-2D/SP, OCUM-2MD3/SP SU11274 (2μM) A, S, D 68
Cisplatin SGC7901 SGC7901/DDP exosome-delivered KD A 62
Doxorubicin GTL-16 n/a PHA665752 (0-300nM) A, R 57
Osteosarcoma Cisplatin SAOS-2 n/a PHA665752 (1μM), anti-HGF ab A, R 45
Multiple myeloma Melphalan + doxorubicin RPMI-8226 RPMI-8226.R5 Inline graphic SU11274 (0–1μmol/L) A, E 29
Doxorubicin U266 n/a KD A 61
Glioma/ Glioblastoma Paclitaxel U251, SHG44 n/a antisense deoxynucleotides A 60
Temozolamide H4, U87 n/a KD 59
Doxorubicin, cisplatin, paclitaxel U-373 Inline graphic n/a KD A 39
Temozolamide U251, U87 Inline graphic n/a SU11274 (5μM), KD AE, H 40
Breast adenocarcinoma Doxorubicin MDA-MB-453, MDA-MB-231 n/a NK1 (300ng/ml) A 44
Doxorubicin MDA-MB-453, T47D n/a Absence of HGF A, R 47
Doxorubicin MDA-MB-231 n/a SU11274 (1 or 2μM), KD D 32
Doxorubicin MCF-7 Inline graphic MCF-7/ADR2 Inline graphic KD A 33
HCC Doxorubicin P5 cells P1(0.5) cells Inline graphic Anti-HGF ab A 34
Colon carcinoma Doxorubicin HT29 SU11274 (1 or 2μM), KD D 32
Uterine sarcoma Doxorubicin MES-SA Inline graphic MES-SA/Dx5 Inline graphic KD A 33
Prostate carcinoma Doxorubicin DU-145 n/a Absence of HGF A, R 47